Europe
Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints.
Research published in Lancet Oncology August 24th analyzed that risk by tumor subtype and patient demographics, looking at 1,044 patients from 60 medical centers throughout the UK.
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
AstraZeneca’s Farxiga (dapagliflozin) dramatically prolonged survival in patients with chronic kidney disease in a Phase III clinical trial.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The trials were identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies that evaluated tapinarof cream, 1% in adults with plaque psoriasis.
The U.S. Food and Drug Administration (FDA) approved Italy-based Cassiopea SpA’s acne treatment Winlevi. Let’s look at how this new acne treatment was developed.
Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.
PRESS RELEASES